Inherited Complete Deficiency of 20-Kilodalton Homologous Restriction Factor (CD59) as a Cause of Paroxysmal Nocturnal Hemoglobinuria
Open Access
- 25 October 1990
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 323 (17) , 1184-1189
- https://doi.org/10.1056/nejm199010253231707
Abstract
PAROXYSMAL nocturnal hemoglobinuria is a rare acquired disease caused by an unusual susceptibility of erythrocytes to the lytic action of complement. The abnormal erythrocytes are thought to originate from the clonal proliferation of bone marrow progenitors altered by somatic mutation.1 Erythrocytes from patients with paroxysmal nocturnal hemoglobinuria have been shown to be deficient in membrane glycoproteins, such as decay-accelerating factor (DAF)2 , 3 and a factor called either homologous restriction factor4 (HRF) or C8-binding protein5 (C8bp). DAF can inhibit the formation and induce the dissociation of C3 convertases of the classical and alternative pathways of complement activation.6 7 8 HRF/C8bp appears to limit the formation of membrane attack complexes (which are composed of C5b, C6, C7, C8, and C9 and capable of causing complement-mediated cytolysis).9 , 10 These inhibitors are anchored to the cell membrane by means of a glycosyl-phosphatidylinositol moiety.11 12 13 14 In addition, other membrane proteins containing glycosyl-phosphatidylinositol moieties,15 such as acetylcholinesterase16 and lymphocyte function-associated antigen 3 (LFA-3),17 are missing from erythrocytes altered by paroxysmal nocturnal hemoglobinuria.18 19 20 These findings suggest that the molecular basis of the defect in this disorder may reflect abnormalities in the biosynthesis of glycosyl-phosphatidylinositol.Keywords
This publication has 42 references indexed in Scilit:
- Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factorClinical and Experimental Immunology, 1990
- Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.Journal of Clinical Investigation, 1989
- Studies on the sensitivity to complement‐mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor)British Journal of Haematology, 1989
- 20 KDa homologous restriction factor of complement resembles T cell activating proteinBiochemical and Biophysical Research Communications, 1989
- A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complementInternational Immunology, 1989
- A family showing inheritance of the Inab phenotypeTransfusion, 1988
- Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.Journal of Clinical Investigation, 1987
- Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipidBiochemistry, 1986
- Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.The Journal of Experimental Medicine, 1986
- Deficiency of the Complement Regulatory Protein, Decay-Accelerating Factor, on Membranes of Granulocytes, Monocytes, and Platelets in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 1985